YIH
DNTH icon

Y-Intercept (HK)’s Dianthus Therapeutics DNTH Stock Holding History

Y-Intercept (HK)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,568
Closed -$731K – 1648
2025
Q3 		$731K Buy
+18,568
New +$475K 0.02% 1111
2024
Q2 		– Sell
-12,090
Closed -$363K – 1504
2024
Q1 		$363K Buy
+12,090
New +$263K 0.03% 871
2022
Q3 		– Sell
-672
Closed -$13K – 1039
2022
Q2 		$13K Buy
+672
New +$16.6K ﹤0.01% 804

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Y-Intercept (HK)'s DNTH Position: Q4 2025 in Review

Y-Intercept (HK) sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 18,568 shares — an estimated $731K sold.

Y-Intercept (HK) first reported a position in DNTH in Q2 2022 and held it in 3 quarters. The position peaked at $731K in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Y-Intercept (HK) reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 18,568 Dianthus Therapeutics shares in Q4 2025, an estimated $731K.
  • Y-Intercept (HK) first reported a position in Dianthus Therapeutics in Q2 2022 and held it in 3 quarters.
  • Y-Intercept (HK)'s Dianthus Therapeutics position peaked at $731K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.